Peter Jenner - Publications

Affiliations: 
Pharmacology Kings College London, London, England, United Kingdom 

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Rota S, Boura I, Batzu L, Titova N, Jenner P, Falup-Pecurariu C, Chaudhuri KR. "Dopamine Agonist Phobia" in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Review of Neurotherapeutics. PMID 32755243 DOI: 10.1080/14737175.2020.1806059  0.43
2020 Sportelli C, Urso D, Jenner P, Chaudhuri KR. Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-Viewpoint. Frontiers in Neurology. 11: 556. PMID 32595595 DOI: 10.3389/Fneur.2020.00556  0.35
2020 van Wamelen DJ, Wan YM, Ray Chaudhuri K, Jenner P. Stress and cortisol in Parkinson's disease. International Review of Neurobiology. 152: 131-156. PMID 32450994 DOI: 10.1016/Bs.Irn.2020.01.005  0.302
2020 van Wamelen DJ, Taddei RN, Calvano A, Titova N, Leta V, Shtuchniy I, Jenner P, Martinez-Martin P, Katunina E, Chaudhuri KR. Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease. Journal of Parkinson's Disease. PMID 32444561 DOI: 10.3233/Jpd-201988  0.349
2019 Chaudhuri KR, Jenner P, Antonini A. Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens". Movement Disorders : Official Journal of the Movement Disorder Society. 34: 1930-1931. PMID 31845760 DOI: 10.1002/Mds.27871  0.323
2019 Asser A, Hikima A, Raki M, Bergström K, Rose S, Juurmaa J, Krispin V, Muldmaa M, Lilles S, Rätsep H, Jenner P, Kõks S, Männistö PT, Taba P. Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 31786692 DOI: 10.1007/S00702-019-02110-Z  0.407
2019 Leta V, Jenner P, Chaudhuri KR, Antonini A. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. Expert Opinion On Drug Safety. PMID 31619083 DOI: 10.1080/14740338.2019.1681966  0.36
2019 Coletto E, Dolan JS, Pritchard S, Gant A, Hikima A, Jackson MJ, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM. Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease. Npj Parkinson's Disease. 5: 10. PMID 31231674 DOI: 10.1038/S41531-019-0081-9  0.419
2019 Chaudhuri KR, Jenner P, Antonini A. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30983023 DOI: 10.1002/Mds.27691  0.374
2018 Antonini A, Jenner P. Apomorphine infusion in advanced Parkinson disease. Nature Reviews. Neurology. PMID 30279608 DOI: 10.1038/S41582-018-0083-Y  0.352
2018 Fisher R, Lincoln L, Jackson MJ, Abbate V, Jenner P, Hider R, Lees A, Rose S. The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease. Phytotherapy Research : Ptr. PMID 29368409 DOI: 10.1002/Ptr.6017  0.56
2017 Titova N, Schapira AHV, Chaudhuri KR, Qamar MA, Katunina E, Jenner P. Nonmotor Symptoms in Experimental Models of Parkinson's Disease. International Review of Neurobiology. 133: 63-89. PMID 28802936 DOI: 10.1016/Bs.Irn.2017.05.018  0.339
2017 Chaudhuri KR, Jenner P. Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28799259 DOI: 10.1002/Mds.27104  0.308
2017 Modo M, Crum WR, Gerwig M, Vernon AC, Patel P, Jackson MJ, Rose S, Jenner P, Iravani MM. Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease. Plos One. 12: e0180733. PMID 28738061 DOI: 10.1371/Journal.Pone.0180733  0.361
2017 Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews. Neuroscience. 18: 509. PMID 28720825 DOI: 10.1038/Nrn.2017.91  0.308
2017 Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews. Neuroscience. PMID 28592904 DOI: 10.1038/Nrn.2017.62  0.334
2017 Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, Chen D, Wang R, Jenner P, Lu JH, Li M, Zhang Z, Tang B, Jin K, Wang Q. Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. Cell Death & Disease. 8: e2854. PMID 28569795 DOI: 10.1038/Cddis.2017.240  0.328
2017 Kim HJ, Jeon BS, Jenner P. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa. International Review of Neurobiology. 132: 295-343. PMID 28554412 DOI: 10.1016/Bs.Irn.2017.01.006  0.466
2017 Pritchard S, Jackson MJ, Hikima A, Lione L, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM. Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia. Plos One. 12: e0175797. PMID 28520722 DOI: 10.1371/Journal.Pone.0175797  0.387
2016 Ray Chaudhuri K, Qamar MA, Rajah T, Loehrer P, Sauerbier A, Odin P, Jenner P. Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future. Npj Parkinson's Disease. 2: 16023. PMID 28725704 DOI: 10.1038/Npjparkd.2016.23  0.339
2016 Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism & Related Disorders. PMID 27979722 DOI: 10.1016/J.Parkreldis.2016.12.003  0.448
2016 Lincoln L, Fisher R, Jackson MJ, Jenner P, Neumeyer J, Sromek AW, Lees AJ, Rose S. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27133947 DOI: 10.1002/Mds.26626  0.407
2016 Stamford J, Scheller D, Jenner P. Parkinson's Inside Out. Journal of Parkinson's Disease. 6: 65-6. PMID 27031860 DOI: 10.3233/Jpd-160792  0.327
2016 Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson's disease. Parkinsonism & Related Disorders. 22: S41-6. PMID 26459660 DOI: 10.1016/J.Parkreldis.2015.09.027  0.341
2015 Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European Journal of Pharmacology. 766: 25-30. PMID 26415982 DOI: 10.1016/J.Ejphar.2015.09.028  0.456
2015 Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Translational Neurodegeneration. 4: 3. PMID 25973178 DOI: 10.1186/2047-9158-4-3  0.38
2015 Brzozowski MJ, Jenner P, Rose S. Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity. Journal of Neural Transmission (Vienna, Austria : 1996). 122: 779-88. PMID 25503828 DOI: 10.1007/S00702-014-1334-8  0.343
2015 Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. European Journal of Pharmacology. 747: 160-5. PMID 25499739 DOI: 10.1016/J.Ejphar.2014.11.038  0.451
2015 Broom L, Jenner P, Rose S. Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity. Experimental Neurology. 263: 1-7. PMID 25218309 DOI: 10.1016/J.Expneurol.2014.09.005  0.311
2014 Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R. Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Medicine. 15: 1288-301. PMID 25201131 DOI: 10.1016/J.Sleep.2014.05.009  0.334
2014 Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson's disease. International Review of Neurobiology. 119: 71-86. PMID 25175961 DOI: 10.1016/B978-0-12-801022-8.00003-9  0.431
2014 Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S. The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats. European Journal of Pharmacology. 741: 304-10. PMID 25160743 DOI: 10.1016/J.Ejphar.2014.08.004  0.437
2014 Jenner P. A late appearance by the dopamine D-3 receptor. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1094-6. PMID 25044342 DOI: 10.1002/Mds.25958  0.361
2014 Iravani MM, Sadeghian M, Rose S, Jenner P. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. Journal of Neural Transmission (Vienna, Austria : 1996). 121: 1493-505. PMID 24781752 DOI: 10.1007/S00702-014-1223-1  0.367
2014 Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Practical Neurology. 14: 310-22. PMID 24699931 DOI: 10.1136/Practneurol-2013-000741  0.303
2014 Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. Adenosine Aâ‚‚A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. Journal of Pharmacological Sciences. 124: 480-5. PMID 24681641 DOI: 10.1254/Jphs.13250Fp  0.405
2014 Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, Kanda T. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology. 231: 2839-49. PMID 24488405 DOI: 10.1007/S00213-014-3454-0  0.376
2014 Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity. Journal of Molecular Neuroscience : Mn. 52: 302-12. PMID 24150990 DOI: 10.1007/S12031-013-0145-Y  0.356
2014 Jackson MJ, Swart T, Pearce RKB, Jenner P. Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets Journal of Neural Transmission. 121: 163-169. PMID 23959162 DOI: 10.1007/S00702-013-1082-1  0.4
2013 Zeng BY, Salvage S, Jenner P. Effect and mechanism of acupuncture on Alzheimer's disease. International Review of Neurobiology. 111: 181-95. PMID 24215923 DOI: 10.1016/B978-0-12-411545-3.00009-2  0.303
2013 Zeng BY, Salvage S, Jenner P. Current development of acupuncture research in Parkinson's disease. International Review of Neurobiology. 111: 141-58. PMID 24215921 DOI: 10.1016/B978-0-12-411545-3.00007-9  0.388
2013 Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacology, Biochemistry, and Behavior. 114: 23-30. PMID 24201052 DOI: 10.1016/J.Pbb.2013.10.022  0.366
2013 Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A. Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents. Bioorganic & Medicinal Chemistry Letters. 23: 5279-82. PMID 23973169 DOI: 10.1016/J.Bmcl.2013.08.007  0.545
2013 Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D. Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. Journal of Parkinson's Disease. 3: 1-11. PMID 23938306 DOI: 10.3233/Jpd-130175  0.341
2013 Jenner P. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease. Neurologic Clinics. 31: S17-35. PMID 23931952 DOI: 10.1016/J.Ncl.2013.04.010  0.41
2013 Kadowaki Horita T, Kobayashi M, Mori A, Jenner P, Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology. 230: 345-52. PMID 23748382 DOI: 10.1007/S00213-013-3158-X  0.378
2013 Ailane S, Long P, Jenner P, Rose S. Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. The European Journal of Neuroscience. 38: 2468-76. PMID 23692556 DOI: 10.1111/Ejn.12231  0.311
2013 Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology & Medicine. 62: 132-44. PMID 23380027 DOI: 10.1016/J.Freeradbiomed.2013.01.018  0.363
2013 Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1072-9. PMID 23125107 DOI: 10.1002/Mds.25218  0.395
2013 Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 24-30. PMID 22927094 DOI: 10.1002/Mds.25032  0.346
2012 Iglesias-González J, Sánchez-Iglesias S, Méndez-Álvarez E, Rose S, Hikima A, Jenner P, Soto-Otero R. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochemical Research. 37: 2150-60. PMID 22821477 DOI: 10.1007/S11064-012-0838-6  0.353
2012 Long P, Samnakay P, Jenner P, Rose S. A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. The European Journal of Neuroscience. 36: 2733-42. PMID 22779921 DOI: 10.1111/J.1460-9568.2012.08189.X  0.326
2012 Tayarani-Binazir KA, Jackson MJ, Strang I, Jairaj M, Rose S, Jenner P. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat. Behavioural Pharmacology. 23: 126-33. PMID 22236652 DOI: 10.1097/Fbp.0B013E32834F9F82  0.395
2012 Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: 1502-8. PMID 22221452 DOI: 10.1111/J.1468-1331.2011.03593.X  0.419
2012 Iravani MM, Mccreary AC, Jenner P. Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia Parkinsonism and Related Disorders. 18: S123-S125. PMID 22166408 DOI: 10.1016/S1353-8020(11)70038-4  0.45
2012 Jenner P. Mitochondria, monoamine oxidase B and Parkinson's disease Basal Ganglia. 2: S3-S7. DOI: 10.1016/J.Baga.2012.06.006  0.384
2011 Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2316-23. PMID 21953831 DOI: 10.1002/Mds.23926  0.367
2011 Brotchie J, Jenner P. New approaches to therapy. International Review of Neurobiology. 98: 123-50. PMID 21907085 DOI: 10.1016/B978-0-12-381328-2.00005-5  0.39
2011 Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 1661-90. PMID 21881839 DOI: 10.1007/S00702-011-0698-2  0.437
2011 Jenner P, McCreary AC, Scheller DKA. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression Journal of Neural Transmission. 118: 1691-1702. PMID 21881838 DOI: 10.1007/S00702-011-0703-9  0.446
2011 Brzozowski MJ, Alcantara SL, Iravani MM, Rose S, Jenner P. The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Research. 1404: 21-30. PMID 21737065 DOI: 10.1016/J.Brainres.2011.05.063  0.35
2011 Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1049-55. PMID 21626550 DOI: 10.1002/Mds.23732  0.369
2011 Papathanou M, Rose S, McCreary A, Jenner P. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. The European Journal of Neuroscience. 33: 2247-54. PMID 21615558 DOI: 10.1111/J.1460-9568.2011.07704.X  0.464
2011 Hansard MJ, Jackson MJ, Smith LA, Rose S, Jenner P. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Behavioural Pharmacology. 22: 269-74. PMID 21522056 DOI: 10.1097/Fbp.0B013E328345Ca37  0.306
2011 Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology. 164: 1357-91. PMID 21486284 DOI: 10.1111/J.1476-5381.2011.01426.X  0.4
2010 Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets Experimental Neurology. 226: 320-327. PMID 20843474 DOI: 10.1016/J.Expneurol.2010.09.007  0.437
2010 Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2059-66. PMID 20721904 DOI: 10.1002/Mds.23249  0.463
2010 Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiology of Disease. 40: 599-607. PMID 20713157 DOI: 10.1016/J.Nbd.2010.08.004  0.378
2010 Bukhatwa S, Zeng BY, Rose S, Jenner P. The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. Brain Research. 1354: 236-42. PMID 20678493 DOI: 10.1016/J.Brainres.2010.07.060  0.385
2010 Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. European Journal of Medicinal Chemistry. 45: 4035-42. PMID 20646792 DOI: 10.1016/J.Ejmech.2010.05.062  0.561
2010 Iczkiewicz J, Broom L, Cooper JD, Wong AM, Rose S, Jenner P. The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. Journal of Neurochemistry. 114: 1792-804. PMID 20626561 DOI: 10.1111/J.1471-4159.2010.06896.X  0.314
2010 Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC. An in vivo pharmacological evaluation of pardoprunox (SLV308) - A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease European Neuropsychopharmacology. 20: 582-593. PMID 20434890 DOI: 10.1016/J.Euroneuro.2010.03.001  0.459
2010 Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? European Neurology. 63: 257-66. PMID 20332641 DOI: 10.1159/000300647  0.354
2010 Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. European Journal of Pharmacology. 635: 109-16. PMID 20303948 DOI: 10.1016/J.Ejphar.2010.03.006  0.407
2010 Bukhatwa S, Zeng BY, Rose S, Jenner P. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Research. 1326: 174-83. PMID 20176003 DOI: 10.1016/J.Brainres.2010.02.045  0.35
2010 Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 377-84. PMID 20108359 DOI: 10.1002/Mds.22960  0.415
2010 Stockwell KA, Scheller DKA, Smith LA, Rose S, Iravani MM, Jackson MJ, Jenner P. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets Experimental Neurology. 221: 79-85. PMID 19833125 DOI: 10.1016/J.Expneurol.2009.10.004  0.417
2010 Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 55-67. PMID 19809864 DOI: 10.1007/S00702-009-0323-9  0.444
2010 Zeng BY, Balfour RH, Jackson MJ, Rose S, Jenner P. Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 45-51. PMID 19771390 DOI: 10.1007/S00702-009-0315-9  0.389
2009 Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism & Related Disorders. 15: S18-23. PMID 20123550 DOI: 10.1016/S1353-8020(09)70829-6  0.436
2009 Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clinical Therapeutics. 31: 2698-711. PMID 20110012 DOI: 10.1016/J.Clinthera.2009.10.018  0.36
2009 Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 1090-9. PMID 19723294 DOI: 10.1111/J.1468-1331.2009.02793.X  0.366
2009 Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handbook of Experimental Pharmacology. 589-615. PMID 19639294 DOI: 10.1007/978-3-540-89615-9_18  0.36
2009 Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, Smith LA, Olanow CW, Jenner P. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction Experimental Neurology. 219: 533-542. PMID 19619533 DOI: 10.1016/J.Expneurol.2009.07.011  0.453
2009 Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 982-9. PMID 19538218 DOI: 10.1111/J.1468-1331.2009.02697.X  0.421
2009 Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism & Related Disorders. 15: 406-13. PMID 19446490 DOI: 10.1016/J.Parkreldis.2008.12.006  0.337
2009 Bukhatwa S, Iravani MM, Zeng BY, Cooper JD, Rose S, Jenner P. An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. Journal of Neurochemistry. 109: 52-9. PMID 19187437 DOI: 10.1111/J.1471-4159.2009.05956.X  0.328
2009 Brzozowski M, Lopez Alcantara S, Iravani M, Rose S, Jenner P. P2.120 iNOS-but not nNOS-inhibition protects against 6-OHDA-induced nigral cell loss in an animal model of PD Parkinsonism & Related Disorders. 15: S122. DOI: 10.1016/S1353-8020(09)70471-7  0.333
2009 Papathanou M, Kooyman E, van der Laan R, Conjeevaram R, Nahas K, Jenner P, Rose S, Mccreary A. P2.090 A preliminary pharmacokinetic study comparing L-Dopa and Duodopa in adult rats Parkinsonism & Related Disorders. 15: S113. DOI: 10.1016/S1353-8020(09)70441-9  0.301
2008 Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Annals of Neurology. 64: S16-29. PMID 19127585 DOI: 10.1002/Ana.21489  0.383
2008 Jenner P. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Movement Disorders : Official Journal of the Movement Disorder Society. 23: S585-98. PMID 18781676 DOI: 10.1002/Mds.22022  0.446
2008 Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature Reviews. Neuroscience. 9: 665-77. PMID 18714325 DOI: 10.1038/Nrn2471  0.421
2008 Jenner P. Dopamine agonists in Parkinson's disease - Focus on non-motor symptoms European Journal of Neurology. 15: 1. PMID 18702735 DOI: 10.1111/J.1468-1331.2008.02211.X  0.406
2008 Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Schapira AH, Jenner P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Experimental Neurology. 212: 522-31. PMID 18571649 DOI: 10.1016/J.Expneurol.2008.04.037  0.368
2008 MacInnes N, Iravani MM, Perry E, Piggott M, Perry R, Jenner P, Ballard C. Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 869-78. PMID 18401540 DOI: 10.1007/S00702-008-0027-6  0.3
2008 Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets Experimental Neurology. 211: 172-179. PMID 18321484 DOI: 10.1016/J.Expneurol.2008.01.019  0.421
2008 Lane EL, Cheetham S, Jenner P. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 423-9. PMID 18250952 DOI: 10.1007/S00702-007-0854-X  0.678
2007 Jenner P. Oxidative stress and Parkinson's disease. Handbook of Clinical Neurology. 83: 507-20. PMID 18808931 DOI: 10.1016/S0072-9752(07)83024-7  0.374
2007 Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental Neurology. 208: 177-84. PMID 17935716 DOI: 10.1016/J.Expneurol.2007.05.002  0.42
2007 Iczkiewicz J, Rose S, Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Experimental Neurology. 207: 95-106. PMID 17643430 DOI: 10.1016/J.Expneurol.2007.05.030  0.322
2007 Hurley MJ, Patel PH, Jackson MJ, Smith LA, Rose S, Jenner P. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. The European Journal of Neuroscience. 26: 171-7. PMID 17614947 DOI: 10.1111/J.1460-9568.2007.05638.X  0.392
2007 Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology. 66: 329-36. PMID 17483689 DOI: 10.1097/Nen.0B013E318053716A  0.328
2007 Kuoppamäki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates Journal of Neural Transmission. 114: 1147-1153. PMID 17446998 DOI: 10.1007/S00702-007-0727-3  0.403
2007 Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 715-9. PMID 17373723 DOI: 10.1002/Mds.21256  0.416
2007 Rose S, Scheller DK, Breidenbach A, Smith L, Jackson M, Stockwell K, Jenner P. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behavioural Pharmacology. 18: 155-60. PMID 17351422 DOI: 10.1097/Fbp.0B013E3280Ebb400  0.376
2007 Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Research. 1133: 110-4. PMID 17196564 DOI: 10.1016/J.Brainres.2006.10.038  0.434
2007 Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental Neurology. 204: 162-70. PMID 17113078 DOI: 10.1016/J.Expneurol.2006.10.005  0.441
2007 Stockwell K, Virley D, Perren M, Iravani M, Jackson M, Rose S, Jenner P. 2.448 Reversal of motor deficits without dyskinesia induction by continuous delivery of ropinirole in MPTP-treated common marmosets Parkinsonism & Related Disorders. 13: S140. DOI: 10.1016/S1353-8020(08)70768-5  0.319
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087  0.436
2006 Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Research. 1118: 239-50. PMID 16962083 DOI: 10.1016/J.Brainres.2006.08.036  0.377
2006 Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. The Journal of Pharmacology and Experimental Therapeutics. 319: 1225-34. PMID 16959959 DOI: 10.1124/Jpet.106.110429  0.385
2006 Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. European Journal of Pharmacology. 546: 82-7. PMID 16925991 DOI: 10.1016/J.Ejphar.2006.07.017  0.41
2006 Zeng BY, Bukhatwa S, Hikima A, Rose S, Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Annals of Neurology. 60: 248-52. PMID 16862581 DOI: 10.1002/Ana.20932  0.4
2006 Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clinical Neuropharmacology. 29: 112-25. PMID 16772809 DOI: 10.1097/01.Wnf.0000220818.71231.Df  0.399
2006 Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology. 66: S24-36. PMID 16717250 DOI: 10.1212/Wnl.66.10_Suppl_4.S24  0.363
2006 Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson MJ, Rose S, Medhurst AD, Jenner P. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome European Journal of Neuroscience. 23: 1766-1774. PMID 16623833 DOI: 10.1111/J.1460-9568.2006.04718.X  0.361
2006 Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. Journal of Neurochemistry. 96: 1315-21. PMID 16464239 DOI: 10.1111/J.1471-4159.2005.03625.X  0.458
2006 Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacology and Therapeutics. 111: 715-728. PMID 16458973 DOI: 10.1016/J.Pharmthera.2005.12.001  0.447
2006 Iravani MM, Haddon CO, Rose S, Jenner P. 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor Brain Research. 1067: 256-262. PMID 16388785 DOI: 10.1016/J.Brainres.2005.10.086  0.379
2006 Lane EL, Cheetham SC, Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Experimental Neurology. 197: 284-90. PMID 16005456 DOI: 10.1016/J.Expneurol.2005.06.006  0.733
2006 Jenner P. A.2 The preclinical profile of rotigotine (Neupro®), a novel non-ergolinic dopamine agonist for the transdermal treatment of Parkinson's Disease Parkinsonism & Related Disorders. 12: 4. DOI: 10.1016/S1353-8020(07)70016-0  0.316
2005 Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamäki M, Obeso JA, Jenner P. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. The European Journal of Neuroscience. 22: 1305-18. PMID 16190886 DOI: 10.1111/J.1460-9568.2005.04308.X  0.363
2005 Hyun DH, Lee M, Halliwell B, Jenner P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. Journal of Neuroscience Research. 82: 232-44. PMID 16130151 DOI: 10.1002/Jnr.20638  0.312
2005 Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. The European Journal of Neuroscience. 22: 317-30. PMID 16045485 DOI: 10.1111/J.1460-9568.2005.04220.X  0.37
2005 Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology. 65: S3-5. PMID 16030291 DOI: 10.1212/Wnl.65.2_Suppl_1.S3  0.477
2005 Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets European Journal of Neuroscience. 21: 3240-3250. PMID 16026462 DOI: 10.1111/J.1460-9568.2005.04169.X  0.372
2005 Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opinion On Investigational Drugs. 14: 729-38. PMID 16004599 DOI: 10.1517/13543784.14.6.729  0.398
2005 Zeng BY, Medhurst AD, Jackson M, Rose S, Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age Mechanisms of Ageing and Development. 126: 760-766. PMID 15888331 DOI: 10.1016/J.Mad.2005.01.008  0.33
2005 Iczkiewicz J, Rose S, Jenner P. Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. The European Journal of Neuroscience. 21: 1911-20. PMID 15869484 DOI: 10.1111/J.1460-9568.2005.04009.X  0.327
2005 Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. The European Journal of Neuroscience. 21: 841-54. PMID 15787691 DOI: 10.1111/J.1460-9568.2005.03915.X  0.437
2005 Lane EL, Cheetham SC, Jenner P. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. The European Journal of Neuroscience. 21: 179-86. PMID 15654855 DOI: 10.1111/J.1460-9568.2004.03834.X  0.715
2005 Dass B, Iravani MM, Huang C, Barsoum J, Engber TM, Galdes A, Jenner P. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat Journal of Neural Transmission. 112: 763-778. PMID 15586304 DOI: 10.1007/S00702-004-0227-7  0.436
2005 Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. The Journal of Pharmacology and Experimental Therapeutics. 312: 1124-31. PMID 15542624 DOI: 10.1124/Jpet.104.076554  0.664
2005 Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 306-14. PMID 15490461 DOI: 10.1002/Mds.20317  0.452
2005 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, Yebenes JD, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, et al. Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) Movement Disorders. 20. DOI: 10.1002/Mds.20519  0.308
2004 Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacology, Biochemistry, and Behavior. 79: 391-400. PMID 15582011 DOI: 10.1016/J.Pbb.2004.07.015  0.407
2004 Gu M, Iravani MM, Irvani M, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry. 91: 1075-81. PMID 15569251 DOI: 10.1111/J.1471-4159.2004.02804.X  0.443
2004 Iczkiewicz J, Rose S, Jenner P. Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Research. Molecular Brain Research. 132: 64-72. PMID 15548430 DOI: 10.1016/J.Molbrainres.2004.09.013  0.337
2004 Iravani MM, Liu L, Rose S, Jenner P. Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration. Brain Research. 1029: 103-13. PMID 15533321 DOI: 10.1016/J.Brainres.2004.09.033  0.353
2004 Zeng BY, Heales SJR, Canevari L, Rose S, Jenner P. Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice Experimental Neurology. 190: 515-524. PMID 15530890 DOI: 10.1016/J.Expneurol.2004.08.022  0.391
2004 Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology. 63: S13-22. PMID 15477581 DOI: 10.1212/Wnl.63.7_Suppl_2.S13  0.452
2004 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/Mds.20243  0.434
2004 Whitehead KJ, Rose S, Jenner P. Halothane Anesthesia Affects NMDA-Stimulated Cholinergic and GABAergic Modulation of Striatal Dopamine Efflux and Metabolism in the Rat In Vivo Neurochemical Research. 29: 835-842. PMID 15098949 DOI: 10.1023/B:Nere.0000018858.64265.E9  0.38
2004 Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Experimental Neurology. 187: 86-93. PMID 15081591 DOI: 10.1016/J.Expneurol.2004.01.018  0.409
2004 Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/Jpet.103.062414  0.412
2004 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates Movement Disorders. 19: 15-21. PMID 14743355 DOI: 10.1002/Mds.10596  0.417
2004 Jenner P, Obeso, Olanow, Brooks, LeWitt, Stocchi, Hauser. Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation Neurology. 62: S47-S55. PMID 14718680 DOI: 10.1212/Wnl.62.1_Suppl_1.S47  0.461
2004 Zeng BY, Smith LA, Pearce RKB, Tel B, Chancharme L, Moachon G, Jenner P. Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets Neuroscience Letters. 354: 6-9. PMID 14698469 DOI: 10.1016/J.Neulet.2003.08.038  0.361
2004 Kase H, Mori A, Jenner P. Adenosine A2A-receptor antagonists: Beyond dopaminergic therapies for Parkinson's disease Drug Discovery Today: Therapeutic Strategies. 1: 51-57. DOI: 10.1016/J.Ddstr.2004.08.016  0.396
2003 Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Current Opinion in Neurology. 16: S3-7. PMID 15180131 DOI: 10.1097/00019052-200312001-00002  0.446
2003 Jenner P. A2A antagonists as novel nondopaminergic therapy for motor dysfunction in PD Neurology. 61: S32-S38. PMID 14663007 DOI: 10.1212/01.Wnl.0000095209.59347.79  0.466
2003 Hurley MJ, Mash DC, Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain Journal of Neural Transmission. 110: 1279-1288. PMID 14628192 DOI: 10.1007/S00702-003-0033-7  0.35
2003 Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. The European Journal of Neuroscience. 18: 2668-72. PMID 14622169 DOI: 10.1046/J.1460-9568.2003.02963.X  0.451
2003 Iravani MM, Jackson MJ, Kuoppamäki M, Smith LA, Jenner P. 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates Journal of Neuroscience. 23: 9107-9115. PMID 14534244 DOI: 10.1523/Jneurosci.23-27-09107.2003  0.453
2003 Gilbert EA, Edwards RJ, Boobis AR, Rose S, Jenner P. Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. Journal of Neural Transmission (Vienna, Austria : 1996). 110: 1091-101. PMID 14523622 DOI: 10.1007/S00702-003-0029-3  0.308
2003 Jenner P. The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications Neurology. 61: S4-S11. PMID 14504374 DOI: 10.1212/Wnl.61.6_Suppl_3.S4  0.459
2003 Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism Pharmacology Biochemistry and Behavior. 75: 627-633. PMID 12895680 DOI: 10.1016/S0091-3057(03)00129-1  0.402
2003 Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure Movement Disorders. 18: 487-495. PMID 12722161 DOI: 10.1002/Mds.10394  0.397
2003 Jenner P, Hunot, Olanow, Beal, Kordower, Tatton, Schapira. Oxidative stress in Parkinson's disease Annals of Neurology. 53: S26-S38. PMID 12666096 DOI: 10.1002/Ana.10483  0.321
2003 Kunikowska G, Jenner P. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease Brain Research. 968: 206-218. PMID 12663090 DOI: 10.1016/S0006-8993(03)02240-6  0.304
2003 Treseder SA, Rose S, Summo L, Jenner P. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat Journal of Neural Transmission. 110: 229-238. PMID 12658372 DOI: 10.1007/S00702-002-0778-4  0.373
2003 Silva MT, Rose S, Hindmarsh JG, Jenner P. Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum Journal of Neural Transmission. 110: 353-362. PMID 12658363 DOI: 10.1007/S00702-002-0791-7  0.415
2003 Cannizzaro C, Tel BC, Rose S, Zeng BY, Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease Molecular Brain Research. 110: 169-176. PMID 12591154 DOI: 10.1016/S0169-328X(02)00555-7  0.389
2003 Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease Parkinsonism and Related Disorders. 9: 131-137. PMID 12573867 DOI: 10.1016/S1353-8020(02)00115-3  0.446
2003 Maratos EC, Jackson MJ, Pearce RKB, Cannizzaro C, Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus) Experimental Neurology. 179: 90-102. PMID 12504871 DOI: 10.1006/Exnr.2002.8055  0.454
2003 McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology. 179: 38-46. PMID 12504866 DOI: 10.1006/Exnr.2002.8050  0.379
2003 Jenner P. Dysfunction of the ubiquitin–proteasome system in Parkinson's disease Journal of Neurochemistry. 85: 1-1. DOI: 10.1046/J.1471-4159.85.S2.1_2.X  0.365
2002 Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, Rice-Evans CA. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion Free Radical Biology and Medicine. 33: 1693-1702. PMID 12488137 DOI: 10.1016/S0891-5849(02)01137-1  0.303
2002 McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. The European Journal of Neuroscience. 16: 2136-48. PMID 12473081 DOI: 10.1046/J.1460-9568.2002.02301.X  0.328
2002 Kuoppamäki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levopoda Movement Disorders. 17: 1312-1317. PMID 12465074 DOI: 10.1002/Mds.10263  0.406
2002 Tel BC, Zeng BY, Cannizzaro C, Pearce RKB, Rose S, Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets Neuroscience. 115: 1047-1058. PMID 12453478 DOI: 10.1016/S0306-4522(02)00535-3  0.389
2002 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates Journal of Pharmacology and Experimental Therapeutics. 303: 952-958. PMID 12438514 DOI: 10.1124/Jpet.102.039743  0.382
2002 Smith LA, Tel BC, Jackson MJ, Hansard M, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P. Repeated administration of piribedil induces less dyskinesia than L-Dopa in MPTP-treated common marmosets: A behavioral and biochemical investigation Movement Disorders. 17: 887-901. PMID 12360537 DOI: 10.1002/Mds.10200  0.46
2002 Pearce RKB, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets Movement Disorders. 17: 877-886. PMID 12360536 DOI: 10.1002/Mds.10238  0.441
2002 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates European Journal of Pharmacology. 451: 157-160. PMID 12231385 DOI: 10.1016/S0014-2999(02)02268-9  0.44
2002 Dass B, Iravani MM, Jackson MJ, Engber TM, Galdes A, Jenner P. Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets Neuroscience. 114: 99-109. PMID 12207958 DOI: 10.1016/S0306-4522(02)00214-2  0.418
2002 McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13: 1437-41. PMID 12167769 DOI: 10.1097/00001756-200208070-00018  0.401
2002 McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neuroscience Letters. 326: 155-8. PMID 12095645 DOI: 10.1016/S0304-3940(02)00296-3  0.363
2002 Smith LA, Jackson MJ, Al-Barghouthy G, Jenner P. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration Journal of Neural Transmission. 109: 123-140. PMID 12075853 DOI: 10.1007/S007020200009  0.344
2002 Spencer JP, Whiteman M, Jenner P, Halliwell B. 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. Journal of Neurochemistry. 81: 122-9. PMID 12067224 DOI: 10.1046/J.1471-4159.2002.00808.X  0.38
2002 Hyun DH, Lee M, Hattori N, Kubo SI, Mizuno Y, Halliwell B, Jenner P. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome Journal of Biological Chemistry. 277: 28572-28577. PMID 12034719 DOI: 10.1074/Jbc.M200666200  0.305
2002 Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P. 6-Hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats Neuroscience Letters. 322: 33-36. PMID 11958837 DOI: 10.1016/S0304-3940(02)00083-6  0.358
2002 Kunikowska G, Jenner P. The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia Biochemical Pharmacology. 63: 1159-1164. PMID 11931849 DOI: 10.1016/S0006-2952(01)00897-8  0.307
2002 Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease Neurology. 58: S1-S8. PMID 11909980 DOI: 10.1212/Wnl.58.Suppl_1.S1  0.476
2002 Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration Neuroscience. 110: 49-58. PMID 11882372 DOI: 10.1016/S0306-4522(01)00562-0  0.361
2002 Lyras L, Zeng BY, McKenzie G, Pearce RKB, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys Journal of Neural Transmission. 109: 53-67. PMID 11793162 DOI: 10.1007/S702-002-8236-2  0.418
2002 Costa S, Iravani MM, Pearce RK, Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. European Journal of Pharmacology. 412: 45-50. PMID 11166735 DOI: 10.1016/S0014-2999(00)00933-X  0.407
2002 Whitehead KJ, Rose S, Jenner P. Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats European Journal of Neuroscience. 14: 851-860. DOI: 10.1046/J.0953-816X.2001.01702.X  0.408
2001 Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. The European Journal of Neuroscience. 14: 1827-32. PMID 11860478 DOI: 10.1046/J.0953-816X.2001.01812.X  0.431
2001 Kunikowska G, Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase Brain Research. 922: 51-64. PMID 11730701 DOI: 10.1016/S0006-8993(01)03149-3  0.361
2001 Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. Journal of Neural Transmission (Vienna, Austria : 1996). 108: 925-41. PMID 11716146 DOI: 10.1007/S007020170013  0.404
2001 Perry NS, Houghton PJ, Sampson J, Theobald AE, Hart S, Lis-Balchin M, Hoult JR, Evans P, Jenner P, Milligan S, Perry EK. In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. The Journal of Pharmacy and Pharmacology. 53: 1347-56. PMID 11697542 DOI: 10.1211/0022357011777846  0.305
2001 Medhurst AD, Zeng BY, Charles KJ, Gray J, Reavill C, Hunter AJ, Shale JA, Jenner P. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment. Neuroscience. 105: 353-64. PMID 11672603 DOI: 10.1016/S0306-4522(01)00190-7  0.37
2001 Pearce RKB, Heikkila M, Linden IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology. 156: 402-409. PMID 11498717 DOI: 10.1007/S002130100733  0.388
2001 McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nature Reviews. Neuroscience. 2: 589-94. PMID 11484002 DOI: 10.1038/35086067  0.353
2001 Ferger B, Themann C, Rose S, Halliwell B, Jenner P. 6-Hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: Implication of peroxynitrite formation Journal of Neurochemistry. 78: 509-514. PMID 11483653 DOI: 10.1046/J.1471-4159.2001.00429.X  0.347
2001 Maratos EC, Jackson MJ, Pearce RK, Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Movement Disorders : Official Journal of the Movement Disorder Society. 16: 631-41. PMID 11481686 DOI: 10.1002/Mds.1149  0.437
2001 Lee MH, Hyun DH, Jenner P, Halliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. Journal of Neurochemistry. 78: 32-41. PMID 11432971 DOI: 10.1046/J.1471-4159.2001.00416.X  0.3
2001 Ferger B, Rose S, Jenner A, Halliwell B, Jenner P. 6-Hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum Neuroreport. 12: 1155-1159. PMID 11338183 DOI: 10.1097/00001756-200105080-00021  0.34
2001 Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends in Neurosciences. 24: 245-7. PMID 11311359 DOI: 10.1016/S0166-2236(00)01789-6  0.356
2001 Hurley MJ, Mash DC, Jenner P. Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease Molecular Brain Research. 87: 271-279. PMID 11245931 DOI: 10.1016/S0169-328X(01)00022-5  0.412
2001 Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RKB, Jenner P. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets European Journal of Neuroscience. 13: 597-608. PMID 11168568 DOI: 10.1046/J.1460-9568.2001.01408.X  0.494
2001 McNaught KSP, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neuroscience Letters. 297: 191-194. PMID 11137760 DOI: 10.1016/S0304-3940(00)01701-8  0.406
2001 Treseder SA, Rose S, Jenner P. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats European Journal of Neuroscience. 13: 162-170. PMID 11135014 DOI: 10.1046/J.0953-816X.2000.01370.X  0.445
2001 Treseder SA, Smith LA, Jenner P. Endogenous dopaminergic tone and dopamine agonist action. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 804-12. PMID 11009183 DOI: 10.1002/1531-8257(200009)15:5<804::Aid-Mds1007>3.0.Co;2-2  0.419
2000 Riedl AG, Watts PM, Douek DC, Edwards RJ, Boobis AR, Rose S, Jenner P. Expression and distribution of CYP2C enzymes in rat basal ganglia Synapse. 38: 392-402. PMID 11044886 DOI: 10.1002/1098-2396(20001215)38:4<392::Aid-Syn4>3.0.Co;2-Z  0.333
2000 Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. Journal of Neurology. 247: 43-50. PMID 10991665 DOI: 10.1007/Pl00007760  0.453
2000 McNaught KSP, Jenner P. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochemical Pharmacology. 60: 979-988. PMID 10974207 DOI: 10.1016/S0006-2952(00)00415-9  0.331
2000 Jenner P, Zeng BY, Smith LA, Pearce RK, Tel B, Chancharme L, Moachon G. Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset. Experimental Brain Research. 133: 178-88. PMID 10968218 DOI: 10.1007/S002210000370  0.425
2000 Hurley MJ, Mash DC, Jenner P. Adenosine A(2A) receptor mRNA expression in Parkinson's disease Neuroscience Letters. 291: 54-58. PMID 10962152 DOI: 10.1016/S0304-3940(00)01371-9  0.346
2000 Alam ZI, Halliwell B, Jenner P. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. Journal of Neurochemistry. 75: 840-6. PMID 10899962 DOI: 10.1046/J.1471-4159.2000.0750840.X  0.33
2000 Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RKB, Jenner P. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset Clinical Neuropharmacology. 23: 133-142. PMID 10895396 DOI: 10.1097/00002826-200005000-00002  0.427
2000 McNaught KSP, Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neuroscience Letters. 285: 61-65. PMID 10788708 DOI: 10.1016/S0304-3940(00)00982-4  0.358
2000 Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. The European Journal of Neuroscience. 12: 1096-104. PMID 10762340 DOI: 10.1046/J.1460-9568.2000.00988.X  0.416
2000 Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP- treated primates Annals of Neurology. 47: S90-S104. PMID 10762136  0.328
2000 Treseder SA, Jackson M, Jenner P. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates British Journal of Pharmacology. 129: 1355-1364. PMID 10742291 DOI: 10.1038/Sj.Bjp.0703189  0.428
2000 Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Experimental Neurology. 162: 321-327. PMID 10739638 DOI: 10.1006/Exnr.2000.7350  0.433
2000 Chadha A, Dawson LG, Jenner PG, Duty S. Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience. 95: 119-26. PMID 10619468 DOI: 10.1016/S0306-4522(99)00413-3  0.332
1999 Jenner P. Genetic susceptibility and the occurrence of Parkinson's disease Parkinsonism & Related Disorders. 5: 173-177. PMID 18591137 DOI: 10.1016/S1353-8020(99)00034-6  0.343
1999 Pearce RKB, Costa S, Jenner P, Marsden CD. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets Journal of Neural Transmission. 106: 663-683. PMID 10907726 DOI: 10.1007/S007020050188  0.365
1999 Gallagher IM, Clow A, Jenner P, Glover V. Long-term effects of pergolide and (-)-deprenyl on 3H-mazindol and 3H-spiperone binding in rat brain. Neurobiology of Aging. 20: 709-13. PMID 10674438 DOI: 10.1016/S0197-4580(99)00026-3  0.334
1999 Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts Neuroscience. 95: 377-388. PMID 10658617 DOI: 10.1016/S0306-4522(99)00457-1  0.398
1999 Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats Neuroscience Letters. 276: 71-74. PMID 10624794 DOI: 10.1016/S0304-3940(99)00762-4  0.404
1999 McNaught KSP, Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures Journal of Neurochemistry. 73: 2469-2476. PMID 10582607 DOI: 10.1046/J.1471-4159.1999.0732469.X  0.32
1999 Marshall KA, Reist M, Jenner P, Halliwell B. The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease. Free Radical Biology & Medicine. 27: 515-20. PMID 10490270 DOI: 10.1016/S0891-5849(99)00094-5  0.38
1999 Rose S, Hindmarsh JG, Jenner P. Neuronal nitric oxide synthase inhibition reduces MPP +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum Journal of Neural Transmission. 106: 477-486. PMID 10443551 DOI: 10.1007/S007020050172  0.423
1999 Dexter DT, Ward RJ, Florence A, Jenner P, Crichton RR. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. Biochemical Pharmacology. 58: 151-5. PMID 10403528 DOI: 10.1016/S0006-2952(99)00079-9  0.342
1999 Pearce RKB, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets Psychopharmacology. 142: 51-60. PMID 10102782 DOI: 10.1007/S002130050861  0.417
1999 Riedl AG, Watts PM, Edwards RJ, Schulz-Utermoehl T, Boobis AR, Jenner P, Marsden CD. Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain Research. 822: 175-91. PMID 10082895 DOI: 10.1016/S0006-8993(99)01113-0  0.353
1998 Watts PM, Riedl AG, Douek DC, Edwards RJ, Boobis AR, Jenner P, Marsden CD. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase Neuroscience. 86: 511-519. PMID 9881865 DOI: 10.1016/S0306-4522(97)00649-0  0.373
1998 Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. Journal of Neurochemistry. 71: 2431-8. PMID 9832141 DOI: 10.1046/J.1471-4159.1998.71062431.X  0.311
1998 Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. Journal of Neurochemistry. 71: 2112-22. PMID 9798937  0.767
1998 McNaught KSP, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease Biochemical Pharmacology. 56: 921-933. PMID 9776302 DOI: 10.1016/S0006-2952(98)00142-7  0.411
1998 Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A(2A) receptors modify motor function in MPTP-treated common marmosets Neuroreport. 9: 2857-2860. PMID 9760134 DOI: 10.1097/00001756-199808240-00032  0.351
1998 Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease Annals of Neurology. 44: S167-S174. PMID 9749590 DOI: 10.1002/Ana.410440725  0.466
1998 Jenner P, Olanow CW. Understanding cell death in Parkinson's disease Annals of Neurology. 44: S72-S84. PMID 9749577 DOI: 10.1002/Ana.410440712  0.377
1998 Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, Schapira AH. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Journal of the Neurological Sciences. 158: 24-9. PMID 9667773 DOI: 10.1016/S0022-510X(98)00095-1  0.362
1998 Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Annals of Neurology. 43: 507-513. PMID 9546333 DOI: 10.1002/Ana.410430415  0.443
1998 Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 234-41. PMID 9539335 DOI: 10.1002/Mds.870130207  0.466
1998 Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 212-20. PMID 9539332 DOI: 10.1002/Mds.870130204  0.319
1998 Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 104: 661-77. PMID 9444566 DOI: 10.1007/Bf01291884  0.36
1998 Jenner P. Symptomatic and neuroprotective effects of dopamine agonists in Parkinson's disease Pathophysiology. 5: 232. DOI: 10.1016/S0928-4680(98)81199-1  0.327
1997 Rose S, Hindmarsh JG, Collins P, Jenner P. The effect of fenfluramine dosage regimen and reduced food intake on levels of 5-HT in rat brain Journal of Neural Transmission. 104: 1339-1351. PMID 9503280 DOI: 10.1007/Bf01294735  0.314
1997 Owen AD, Schapira AHV, Jenner P, Marsden CD. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies Journal of Neural Transmission, Supplement. 167-173. PMID 9470137 DOI: 10.1007/978-3-7091-6846-2_14  0.355
1997 Marshall KA, Daniel SE, Cairns N, Jenner P, Halliwell B. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochemical and Biophysical Research Communications. 240: 84-7. PMID 9367887 DOI: 10.1006/Bbrc.1997.7604  0.379
1997 Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. Journal of Neurochemistry. 69: 1326-9. PMID 9282961 DOI: 10.1046/J.1471-4159.1997.69031326.X  0.758
1997 Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. Journal of Neurochemistry. 69: 1196-203. PMID 9282943 DOI: 10.1046/J.1471-4159.1997.69031196.X  0.344
1997 Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse (New York, N.Y.). 26: 301-16. PMID 9183819 DOI: 10.1002/(Sici)1098-2396(199707)26:3<301::Aid-Syn11>3.0.Co;2-Y  0.41
1997 Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. Journal of Neural Transmission (Vienna, Austria : 1996). 104: 67-75. PMID 9085194 DOI: 10.1007/Bf01271295  0.461
1997 McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration : a Journal For Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration. 5: 265-74. PMID 8910905 DOI: 10.1006/Neur.1996.0035  0.42
1997 Urwyler S, Campbell E, Fricker G, Jenner P, Lemaire M, McAllister KH, Neijt HC, Park CK, Perkins M, Rudin M, Sauter A, Smith L, Wiederhold KH, Müller W. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 35: 655-69. PMID 8887975 DOI: 10.1016/0028-3908(96)84637-5  0.348
1997 Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 522-32. PMID 8866493 DOI: 10.1002/Mds.870110507  0.412
1997 Seaton TA, Jenner P, Marsden CD. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. Journal of Neural Transmission (Vienna, Austria : 1996). 103: 315-29. PMID 8739843 DOI: 10.1007/Bf01271243  0.45
1997 Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. Journal of Neural Transmission (Vienna, Austria : 1996). 103: 249-60. PMID 8739837 DOI: 10.1007/Bf01271237  0.408
1997 Kanda T, Jackson MJ, Smith L, Pearce RK, Kase H, Kuwana Y, Jenner P. 1564 Adenosine A2α antagonists are antiparkinsonian in MPTP treated primates Neuroscience Research. 28: S202. DOI: 10.1016/S0168-0102(97)90552-6  0.349
1996 Riedl AG, Watts PM, Edwards RJ, Boobis AR, Jenner P, Marsden CD. Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Research. 743: 324-328. PMID 9017262 DOI: 10.1016/S0006-8993(96)00746-9  0.35
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. European Journal of Pharmacology. 318: 283-93. PMID 9016916 DOI: 10.1016/S0014-2999(96)00798-4  0.357
1996 Seaton TA, Jenner P, Marsden CD. Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. Biochemical Pharmacology. 52: 1657-1663. PMID 8986127 DOI: 10.1016/S0006-2952(96)00452-2  0.335
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology. 128: 362-70. PMID 8986007 DOI: 10.1007/S002130050146  0.359
1996 Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease Neurology. 47. PMID 8959985 DOI: 10.1212/Wnl.47.6_Suppl_3.161S  0.368
1996 Hurley MJ, Stubbs CM, Jenner P, Marsden CD. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neuroscience Letters. 214: 75-8. PMID 8878087 DOI: 10.1016/0304-3940(96)12884-6  0.395
1996 McNaught KS, Thull U, Carrupt P, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neuroscience Letters. 206: 37-40. PMID 8848276 DOI: 10.1016/0304-3940(96)12419-8  0.355
1996 Spencer JP, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, Halliwell B. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radical Research. 24: 95-105. PMID 8845917 DOI: 10.3109/10715769609088005  0.308
1996 Hurley MJ, Jolkkonen J, Stubbs CM, Jenner P, Marsden CD. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Research. 709: 259-64. PMID 8833762 DOI: 10.1016/0006-8993(95)01309-1  0.417
1996 Rose S, Hunt S, Collins P, Hindmarsh JG, Jenner P. Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats Neurodegeneration. 5: 145-152. PMID 8819135 DOI: 10.1006/Neur.1996.0021  0.318
1996 Pearce RKB, Collins P, Jenner P, Emmett C, Marsden CD. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset Synapse. 23: 192-200. PMID 8807747 DOI: 10.1002/(Sici)1098-2396(199607)23:3<192::Aid-Syn8>3.0.Co;2-3  0.373
1996 Zeng B‐, Jenner P, Marsden CD. Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery. Movement Disorders. 11: 43-52. PMID 8771066 DOI: 10.1002/Mds.870110109  0.368
1996 Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Movement Disorders : Official Journal of the Movement Disorder Society. 10: 731-40. PMID 8749992 DOI: 10.1002/Mds.870100606  0.433
1996 Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity. Journal of Neural Transmission. General Section. 101: 65-82. PMID 8695058 DOI: 10.1007/Bf01271546  0.335
1996 Owen AD, Schapira AHV, Jenner P, Marsden CD. Oxidative stress and Parkinson's disease Annals of the New York Academy of Sciences. 786: 217-223. PMID 8687021 DOI: 10.1111/J.1749-6632.1996.Tb39064.X  0.411
1996 Smith L, De Salvia M, Jenner P, Marsden CD. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 125-35. PMID 8684381 DOI: 10.1002/Mds.870110203  0.469
1996 McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochemical Pharmacology. 52: 29-34. PMID 8678905 DOI: 10.1016/0006-2952(96)00133-5  0.42
1996 Fernandez A, De Ceballos ML, Rose S, Jenner P, Marsden CD. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease Brain. 119: 823-830. PMID 8673494 DOI: 10.1093/Brain/119.3.823  0.385
1996 Silva MT, Watts PM, Jenner P. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death Bmj (Clinical Research Ed.). 312. PMID 8597747 DOI: 10.1136/Bmj.312.7032.703  0.335
1995 Brunner-Guenat M, Carrupt PA, Lisa G, Testa B, Rose S, Thomas K, Jenner P, Ventura P. Esters of l-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism Journal of Pharmacy and Pharmacology. 47: 861-869. PMID 8583357 DOI: 10.1111/J.2042-7158.1995.Tb05755.X  0.322
1995 Collins P, Broekkamp CL, Jenner P, Marsden CD. Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains. Psychopharmacology. 112: 437-44. PMID 7871054 DOI: 10.1007/Bf02244891  0.324
1995 Collins P, Broekkamp CL, Jenner P, Marsden CD. Electromyographical differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat. Psychopharmacology. 112: 428-36. PMID 7871053 DOI: 10.1007/Bf02244890  0.371
1995 Fernandez A, Jenner P, Marsden CD, De Ceballos ML. Characterization of neurotensin-like immunoreactivity in human basal ganglia: increased neurotensin levels in substantia nigra in Parkinson's disease. Peptides. 16: 339-46. PMID 7784265 DOI: 10.1016/0196-9781(94)00141-3  0.393
1995 Gnanalingham KK, Jenner P, Hunter AJ, Marsden CD. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology. 117: 287-297. PMID 7770604 DOI: 10.1007/Bf02246103  0.465
1995 Gnanalingham KK, Smith LA, Jenner P, Erol DD, Hunter AJ, Marsden CD. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset Psychopharmacology. 117: 275-286. PMID 7770603 DOI: 10.1007/Bf02246102  0.405
1995 Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. Biochemical Pharmacology. 49: 1185-93. PMID 7763300 DOI: 10.1016/0006-2952(95)00035-X  0.41
1995 Jenner P, Schwartz JC, Giros N, Matres MP, Sibley DR, Monsma FJ, Sokoloff P, Martres MP, Giros B, Martin GE, Williams M, Pettibone DJ, Nomoto M, Stahl S, Coleman RJ, ... ... Jenner PG, et al. The rationale for the use of dopamine agonists in parkinson's disease Neurology. 45: S6-S12. PMID 7715795 DOI: 10.1212/Wnl.45.3_Suppl_3.S6  0.452
1995 McNaught KS, Altomare C, Cellamare S, Carotti A, Thull U, Carrupt P, Testa B, Jenner P, Marsden CD. Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroreport. 6: 1105-1108. PMID 7662887 DOI: 10.1097/00001756-199505300-00008  0.31
1995 Zeng BY, Jolkkonen J, Jenner P, Marsden CD. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 66: 19-28. PMID 7637869 DOI: 10.1016/0306-4522(94)00574-O  0.352
1995 Ward RJ, Dexter D, Florence A, Aouad F, Hider R, Jenner P, Crichton RR. Brain iron in the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism Biochemical Pharmacology. 49: 1821-1826. PMID 7598744 DOI: 10.1016/0006-2952(94)00521-M  0.549
1995 Spencer JP, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport. 6: 1480-4. PMID 7579129 DOI: 10.1097/00001756-199507310-00004  0.438
1995 MacKenzie GM, Jenner P, Marsden CD. The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum. Neuroscience. 67: 357-71. PMID 7545792 DOI: 10.1016/0306-4522(94)00621-B  0.356
1995 Silva MT, Rose S, Hindmarsh JG, Aislaitner G, Gorrod JW, Moore PK, Jenner P, Marsden CD. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. British Journal of Pharmacology. 114: 257-8. PMID 7533610 DOI: 10.1111/J.1476-5381.1995.Tb13219.X  0.43
1995 Jolkkonen J, Jenner P, Marsden CD. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Molecular Brain Research. 32: 297-307. PMID 7500841 DOI: 10.1016/0169-328X(95)00084-6  0.392
1995 Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset European Journal of Pharmacology. 277: 235-241. PMID 7493614 DOI: 10.1016/0014-2999(95)00086-Z  0.367
1995 Jolkkonen J, Granata R, Jenner P, Marsden CD. Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum Neuropeptides. 29: 109-114. PMID 7477761 DOI: 10.1016/0143-4179(95)90093-4  0.402
1994 Rose S, Hindmarsh JG, Steiger MJ, Bhatt M, Quinn NP, Jenner P, Marsden CD. Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. Clinical Neuropharmacology. 17: 260-9. PMID 9316671 DOI: 10.1097/00002826-199406000-00005  0.301
1994 Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease Annals of Neurology. 35: 38-44. PMID 8285590 DOI: 10.1002/Ana.410350107  0.378
1994 Rose S, Jenner P, Marsden CD. Chronic administration does not alter the accumulation of L-dopa into muscle. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 167-72. PMID 8196677 DOI: 10.1002/Mds.870090207  0.345
1994 Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 92-7. PMID 8139611 DOI: 10.1002/Mds.870090115  0.306
1994 Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease Annals of Neurology. 36: 356-361. PMID 8080243 DOI: 10.1002/Ana.410360306  0.368
1994 Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Annals of Neurology. 36: 348-355. PMID 8080242 DOI: 10.1002/Ana.410360305  0.401
1994 Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Annals of Neurology. 36: 876-881. PMID 7998774 DOI: 10.1002/Ana.410360612  0.305
1994 Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience. 61: 73-9. PMID 7969897 DOI: 10.1016/0306-4522(94)90061-2  0.383
1994 Spencer JP, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. Febs Letters. 353: 246-50. PMID 7957867 DOI: 10.1016/0014-5793(94)01056-0  0.742
1994 Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat. Neuropharmacology. 33: 647-55. PMID 7936100 DOI: 10.1016/0028-3908(94)90170-8  0.381
1994 Dexter DT, Nanayakkara I, Goss-Sampson MA, Muller DPR, Harding AE, Marsden CD, Jenner P. Nigral dopaminergic cell loss in vitamin E deficient rats Neuroreport. 5: 1773-1776. PMID 7827329 DOI: 10.1097/00001756-199409080-00022  0.303
1994 Jolkkonen J, Jenner P, Marsden CD. GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment. Neuroscience Letters. 180: 273-276. PMID 7535410 DOI: 10.1016/0304-3940(94)90537-1  0.326
1994 de Ceballos ML, Fernandez A, Jenner P, Marsden CD. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients. Neuroscience Letters. 160: 163-6. PMID 7504224 DOI: 10.1016/0304-3940(93)90404-9  0.391
1993 Čičin-Šain L, Jenner P. Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats. Journal of the Neurological Sciences. 115: 105-110. PMID 8468585 DOI: 10.1016/0022-510X(93)90074-9  0.4
1993 Rose S, Nomoto M, Jackson EA, Gibb WR, Jaehnig P, Jenner P, Marsden CD. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. European Journal of Pharmacology. 230: 177-85. PMID 8422900 DOI: 10.1016/0014-2999(93)90800-W  0.38
1993 Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. Journal of Neurochemistry. 60: 197-203. PMID 8417140 DOI: 10.1111/J.1471-4159.1993.Tb05838.X  0.345
1993 Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse (New York, N.Y.). 14: 184-94. PMID 8332947 DOI: 10.1002/Syn.890140212  0.396
1993 Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine Movement Disorders. 8: 129-133. PMID 8097279 DOI: 10.1002/Mds.870080202  0.452
1993 Rose S, Jenner P, Marsden CD. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat. The Journal of Pharmacy and Pharmacology. 45: 725-30. PMID 7901371 DOI: 10.1111/J.2042-7158.1993.Tb07097.X  0.351
1993 Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. European Journal of Pharmacology. 229: 203-9. PMID 1362704 DOI: 10.1016/0014-2999(92)90556-J  0.415
1992 Jenner P. Parkinson's disease: pathological mechanisms and actions of piribedil. Journal of Neurology. 239. PMID 1634907 DOI: 10.1007/Bf00819559  0.481
1992 Cheng CH, Costall B, Hamburger M, Hostettmann K, Naylor RJ, Wang Y, Jenner P. Toxic effects of solstitialin A 13-acetate and cynaropicrin from Centaurea solstitialis L. (Asteraceae) in cell cultures of foetal rat brain. Neuropharmacology. 31: 271-7. PMID 1630595 DOI: 10.1016/0028-3908(92)90177-Q  0.304
1992 Stocchi F, Ruggieri S, Carta A, Ryatt J, Quinn N, Jenner P, Marsden CD, Agnoli A. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 249-56. PMID 1620143 DOI: 10.1002/Mds.870070311  0.341
1992 Blunt SB, Jenner P, Marsden CD. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa. Experimental Brain Research. 88: 326-40. PMID 1577107 DOI: 10.1007/Bf02259108  0.363
1992 Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. Brain muscarinic cholinergic receptors in Huntington's disease. Journal of Neurology. 239: 103-4. PMID 1532417 DOI: 10.1007/Bf00862983  0.325
1992 Dexter DT, Jenner P, Schapira AHV, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia Annals of Neurology. 32: S94-S100. PMID 1510387 DOI: 10.1002/Ana.410320716  0.35
1992 Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease Annals of Neurology. 32: S82-S87. PMID 1510385 DOI: 10.1002/Ana.410320714  0.379
1992 Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease Neurology. 42: 2241-2241. PMID 1461374 DOI: 10.1212/Wnl.42.12.2241  0.382
1992 Blunt SB, Jenner P, Marsden CD. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Research. 582: 299-311. PMID 1393551 DOI: 10.1016/0006-8993(92)90147-2  0.427
1992 Taylor MD, De Ceballos ML, Rose S, Jenner P, Marsden CD. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. European Journal of Pharmacology. 219: 183-92. PMID 1385171 DOI: 10.1016/0014-2999(92)90295-F  0.39
1992 Lange KW, Löschmann PA, Wachtel H, Horowski R, Jähnig P, Jenner P, Marsden CD. Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. European Journal of Pharmacology. 212: 247-52. PMID 1350996 DOI: 10.1016/0014-2999(92)90337-4  0.444
1992 Thomas KL, Rose S, Jenner P, Marsden CD. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum Biochemical Pharmacology. 44: 83-91. PMID 1321631 DOI: 10.1016/0006-2952(92)90041-G  0.412
1992 Thomas KL, Rose S, Jenner P, Marsden CD. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation Biochemical Pharmacology. 44: 73-82. PMID 1321630 DOI: 10.1016/0006-2952(92)90040-P  0.397
1992 Fernandez A, Ceballos MLd, Jenner P, Marsden CD. Striatal neuropeptide levels in Parkinson's disease patients. Neuroscience Letters. 145: 171-174. PMID 1281532 DOI: 10.1016/0304-3940(92)90014-X  0.373
1992 DE CEBALLOS ML, FERNANDEZ A, JENNER P, MARSDEN CD. BASAL GANGLIA NEUROPEPTIDE ALTERATIONS IN PARKINSON??S DISEASE AND CONTROLS BEARING LEWY BODIES Behavioural Pharmacology. 3: 75. DOI: 10.1097/00008877-199204001-00233  0.35
1992 Kebabian JW, DeNinno M, Britton D, Schoenleber R, Jenner P, Smith L, Williams M. A 77636, A DOPAMINE (DA) D-1 RECEPTOR AGONIST WITH EFFICACY IN THE MPTP MARMOSET MODEL OF PARKINSONISM. Clinical Neuropharmacology. 15: 601B. DOI: 10.1097/00002826-199202001-01173  0.404
1992 Jenner P. What process causes nigral cell death in Parkinson's disease? Neurologic Clinics. 10: 387-403. DOI: 10.1016/S0733-8619(18)30217-2  0.349
1991 Maret G, Testa B, Jenner P, el Tayar N, Carrupt PA. The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metabolism Reviews. 22: 291-332. PMID 2253555 DOI: 10.3109/03602539009041087  0.365
1991 Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD. Mitochondrial DNA analysis in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 294-7. PMID 1979656 DOI: 10.1002/Mds.870050406  0.344
1991 Blunt S, Jenner P, Marsden CD. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience. 40: 453-464. PMID 1902916 DOI: 10.1016/0306-4522(91)90133-9  0.421
1991 Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia Brain. 114: 1953-1975. PMID 1832073 DOI: 10.1093/Brain/114.4.1953  0.359
1991 Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurologica Scandinavica. 84: 6-15. PMID 1801537 DOI: 10.1111/J.1600-0404.1991.Tb05013.X  0.386
1991 Löschmann PA, Smith LA, Lange KW, Jaehnig P, Jenner P, Marsden CD. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Psychopharmacology. 105: 303-309. PMID 1686813 DOI: 10.1007/Bf02244422  0.346
1991 Blunt SB, Jenner P, Marsden CD. The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography Neuroscience. 43: 95-110. PMID 1681462 DOI: 10.1016/0306-4522(91)90420-S  0.42
1991 Rose S, Jenner P, Marsden CD. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment. Journal of Pharmacy and Pharmacology. 43: 325-330. PMID 1680174 DOI: 10.1111/J.2042-7158.1991.Tb06698.X  0.343
1991 Collins P, Broekkamp CLE, Jenner P, Marsden CD. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology. 103: 503-512. PMID 1676528 DOI: 10.1007/Bf02244250  0.337
1991 Taylor MD, de Ceballos ML, Jenner P, Marsden CD. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat. Biochemical Pharmacology. 41: 1385-91. PMID 1673340 DOI: 10.1016/0006-2952(91)90112-I  0.391
1991 Wang Y, Hamburger M, Cheng CHK, Costall B, Naylor RJ, Jenner P, Hostettmann K. Neurotoxic Sesquiterpenoids from the Yellow Star ThistleCentaurea solstitialis L. (Asteraceae) Helvetica Chimica Acta. 74: 117-123. DOI: 10.1002/Hlca.19910740114  0.324
1990 Rose S, Nomoto M, Jenner P, Marsden CD. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochemical Pharmacology. 38: 3677-81. PMID 2597167 DOI: 10.1016/0006-2952(89)90572-8  0.434
1990 Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD. Decreased ferritin levels in brain in Parkinson's disease Journal of Neurochemistry. 55: 16-20. PMID 2355217 DOI: 10.1111/J.1471-4159.1990.Tb08814.X  0.377
1990 Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease Journal of Neurochemistry. 54: 823-827. PMID 2154550 DOI: 10.1111/J.1471-4159.1990.Tb02325.X  0.354
1990 Blunt SB, Jenner P, Marsden CD. Chapter 56 The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats Progress in Brain Research. 82: 493-498. PMID 2127116 DOI: 10.1016/S0079-6123(08)62639-4  0.421
1990 Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in parkinson's disease Journal of Neurochemistry. 55: 2142-2145. PMID 2121905 DOI: 10.1111/J.1471-4159.1990.Tb05809.X  0.371
1990 Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. European Journal of Pharmacology. 181: 97-103. PMID 2117541 DOI: 10.1016/0014-2999(90)90249-6  0.409
1990 Raisman-Vozari R, Girault JA, Moussaoui S, Feuerstein C, Jenner P, Marsden CD, Agid Y. Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Research. 507: 45-50. PMID 2105823 DOI: 10.1016/0006-8993(90)90520-L  0.438
1990 Rose S, Jenner P, Marsden C. The effect of carbidopa on the phannacokinetics of L-dihydroxyphenylalanine in the rat European Journal of Pharmacology. 183: 968-969. DOI: 10.1016/0014-2999(90)92809-W  0.314
1989 de Ceballos ML, Baker M, Rose S, Jenner P, Marsden CD. Do enkephalins in basal ganglia mediate a physiological motor rest mechanism? Movement Disorders : Official Journal of the Movement Disorder Society. 1: 223-33. PMID 3504246 DOI: 10.1002/Mds.870010402  0.34
1989 Rose S, Jenner P, Marsden CD. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 117-25. PMID 3221899 DOI: 10.1002/Mds.870030203  0.374
1989 Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. European Journal of Pharmacology. 156: 197-206. PMID 2977118 DOI: 10.1016/0014-2999(88)90322-6  0.398
1989 Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease Journal of Neurochemistry. 52: 381-389. PMID 2911023 DOI: 10.1111/J.1471-4159.1989.Tb09133.X  0.345
1989 Nomoto M, Jenner P, Marsden CD. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neuroscience Letters. 93: 275-80. PMID 2907373 DOI: 10.1016/0304-3940(88)90095-X  0.376
1989 Chivers JK, Reavill C, Jenner P, Marsden CD. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation. The Journal of Pharmacy and Pharmacology. 40: 613-9. PMID 2907027 DOI: 10.1111/J.2042-7158.1988.Tb05320.X  0.407
1989 Nomoto M, Stahl S, Jenner P, Marsden CD. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 2: 37-45. PMID 2904119 DOI: 10.1002/Mds.870020105  0.425
1989 Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. Journal of Neurochemistry. 53: 692-7. PMID 2760616 DOI: 10.1111/J.1471-4159.1989.Tb11759.X  0.332
1989 Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease Journal of Neurochemistry. 52: 1830-1836. PMID 2723638 DOI: 10.1111/J.1471-4159.1989.Tb07264.X  0.356
1989 Jenner P. Clues to the mechanism underlying dopamine cell death in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 22-28. PMID 2666576 DOI: 10.1136/Jnnp.52.Suppl.22  0.414
1989 Löschmann PA, Chong PN, Nomoto M, Tepper PG, Horn AS, Jenner P, Marsden CD. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437 European Journal of Pharmacology. 166: 373-380. PMID 2572426 DOI: 10.1016/0014-2999(89)90348-8  0.365
1989 Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 261-5. PMID 2571082 DOI: 10.1002/mds.870040307  0.329
1989 Jackson EA, Jenner P, Marsden CD. Behavioural and morphological changes following treatment with GM-1 ganglioside of rats with an electrolytic lesion of the substantia nigra. Neuropharmacology. 28: 543-55. PMID 2569173 DOI: 10.1016/0028-3908(89)90132-9  0.397
1989 Chivers JK, Reavill C, Jenner P, Marsden CD. Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs. The Journal of Pharmacy and Pharmacology. 41: 106-11. PMID 2568417 DOI: 10.1111/J.2042-7158.1989.Tb06403.X  0.413
1989 Stewart BR, Jenner P, Marsden CD. Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. European Journal of Pharmacology. 162: 101-7. PMID 2524394 DOI: 10.1016/0014-2999(89)90608-0  0.306
1989 Rose S, Nomoto M, Jackson EA, Gibb WRG, Jenner P, Marsden CD. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology. 28: 1211-1216. PMID 2512516 DOI: 10.1016/0028-3908(89)90213-X  0.441
1989 Ueki A, Chong P, Albanese A, Rose S, Chivers J, Jenner P, Marsden C. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology. 28: 1089-1097. PMID 2510050 DOI: 10.1016/0028-3908(89)90122-6  0.44
1989 Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neuroscience Letters. 101: 305-310. PMID 2505199 DOI: 10.1016/0304-3940(89)90550-8  0.424
1989 Gibb WR, Terruli M, Lees AJ, Jenner P, Marsden CD. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 53-74. PMID 2494438 DOI: 10.1002/Mds.870040109  0.343
1988 Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. European Neurology. 54-8. PMID 3322837 DOI: 10.1159/000116193  0.324
1988 Mesnil M, Testa B, Jenner P. Ex vivo inhibition of rat brain cytochrome P-450 activity by stiripentol. Biochemical Pharmacology. 37: 3619-22. PMID 3178875 DOI: 10.1016/0006-2952(88)90393-0  0.307
1988 Willoughby J, Glover V, Sandler M, Albanese A, Jenner P, Marsden CD. Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity Neuroscience Letters. 90: 100-106. PMID 3137508 DOI: 10.1016/0304-3940(88)90794-X  0.336
1988 Albanese A, Jenner P, Marsden CD, Stephenson JD. Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience Letters. 87: 46-50. PMID 3132651 DOI: 10.1016/0304-3940(88)90143-7  0.375
1988 Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. The Journal of Pharmacy and Pharmacology. 40: 415-21. PMID 2901473 DOI: 10.1111/J.2042-7158.1988.Tb06306.X  0.365
1988 Jenner P, Boyce S, Marsden CD. Receptor changes during chronic dopaminergic stimulation. Journal of Neural Transmission-Supplement. 27: 161-175. PMID 2900291 DOI: 10.1007/978-3-7091-8954-2_14  0.453
1988 Hong M, Roots EJ, Jenner P, Marsden CD. The effect of long-term treatment with amine-depleting drugs or chlorpromazine on alpha-adrenoreceptors and 5-HT2 receptors in the brain of the rat. Neuropharmacology. 27: 519-27. PMID 2899303 DOI: 10.1016/0028-3908(88)90135-9  0.317
1988 Cooper DR, Marrel C, van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. The Journal of Pharmacy and Pharmacology. 39: 809-18. PMID 2891818 DOI: 10.1111/J.2042-7158.1987.Tb05123.X  0.406
1988 Moser A, Reavill C, Liebetrau A, Jenner P, Marsden CD, Cramer H. Dopamine and somatostatin modulated adenylate cyclase activity in the rat caudate-putamen following unilateral cortical ablation. Experimental Brain Research. 68: 406-10. PMID 2891560 DOI: 10.1007/Bf00248805  0.434
1988 Taquet H, Nomoto M, Rose S, Jenner P, Javoy-Agid F, Mauborgne A, Benoliel JJ, Marsden CD, Legrand JC, Agid Y, Hamon M, Cesselin F. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment. Neuropeptides. 12: 105-110. PMID 2468106 DOI: 10.1016/0143-4179(88)90039-X  0.415
1987 Rupniak NM, Prestwich SA, Horton RW, Jenner P, Marsden CD. Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. Journal of Neural Transmission. 68: 113-25. PMID 3806083 DOI: 10.1007/Bf01244643  0.402
1987 De Ceballos ML, Boyce S, Jenner P, Marsden CD. Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. European Journal of Pharmacology. 130: 305-9. PMID 3792452 DOI: 10.1016/0014-2999(86)90282-7  0.437
1987 Dexter DT, Boyce S, Jenner P, Marsden CD. Chronic trifluoperazine treatment does not induce lipid peroxidation in the rat cortex Neuroscience Letters. 76: 368-371. PMID 3587766 DOI: 10.1016/0304-3940(87)90431-9  0.326
1987 De Ceballos ML, Boyce S, Taylor M, Jenner P, Marsden CD. Age-related decreases in the concentration of Met- and Leu-enkephalin and neurotensin in the basal ganglia of rats. Neuroscience Letters. 75: 113-7. PMID 3574764 DOI: 10.1016/0304-3940(87)90085-1  0.357
1987 Marsden CD, Jenner PG. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Ciba Foundation Symposium. 126: 239-56. PMID 3556086 DOI: 10.1002/9780470513422.ch15  0.326
1987 Dewar D, Jenner P, Marsden CD. Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. Biochemical Pharmacology. 36: 1738-1741. PMID 3297065 DOI: 10.1016/0006-2952(87)90062-1  0.326
1987 Waters CM, Hunt SP, Jenner P, Marsden CD. Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research. 412: 244-53. PMID 3038264 DOI: 10.1016/0006-8993(87)91130-9  0.332
1987 Waters CM, Hunt SP, Jenner P, Marsden CD. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience. 23: 1025-39. PMID 2893993 DOI: 10.1016/0306-4522(87)90178-3  0.4
1987 Testa B, el Tayar N, Carrupt PA, Van de Waterbeemd H, Kilpatrick GJ, Jenner P, Marsden CD. The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses. The Journal of Pharmacy and Pharmacology. 39: 767-8. PMID 2890751 DOI: 10.1111/J.2042-7158.1987.Tb06991.X  0.347
1987 Hong M, Kilpatrick GJ, Jenner P, Marsden CD. Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat. Neuropharmacology. 26: 1061-9. PMID 2889161 DOI: 10.1016/0028-3908(87)90249-8  0.413
1987 Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 26: 931-40. PMID 2889159 DOI: 10.1016/0028-3908(87)90072-4  0.44
1987 Cooper DR, Marrel C, van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. The Journal of Pharmacy and Pharmacology. 39: 627-35. PMID 2888854 DOI: 10.1111/J.2042-7158.1987.Tb03441.X  0.366
1987 Hong M, Jenner P, Marsden CD. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats. Neuropharmacology. 26: 237-245. PMID 2884588 DOI: 10.1016/0028-3908(87)90214-0  0.427
1987 Kelly E, Jenner P, Marsden CD. Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats. The Journal of Pharmacy and Pharmacology. 39: 196-202. PMID 2883284 DOI: 10.1111/J.2042-7158.1987.Tb06248.X  0.443
1987 Chivers J, Jenner P, Marsden CD. Pharmacological characterization of binding sites identified in rat brain following in vivo administration of [3H]-spiperone. British Journal of Pharmacology. 90: 467-78. PMID 2882801 DOI: 10.1111/J.1476-5381.1987.Tb11196.X  0.403
1987 Weller ME, Rose S, Jenner P, Marsden CD. In vitro characterisation of dopamine receptors in the superior colliculus of the rat. Neuropharmacology. 26: 347-54. PMID 2438586 DOI: 10.1016/0028-3908(87)90187-0  0.399
1986 Davis AS, Jenner P, Marsden CD. A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine British Journal of Pharmacology. 87: 129-137. PMID 3955297 DOI: 10.1111/J.1476-5381.1986.Tb10164.X  0.399
1986 Simpson MDC, Jenner P, Marsden CD. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat Biochemical Pharmacology. 35: 3501-3506. PMID 3768037 DOI: 10.1016/0006-2952(86)90618-0  0.386
1986 Simpson MDC, Jenner P, Marsden CD. Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat Biochemical Pharmacology. 35: 3203-3208. PMID 3768017 DOI: 10.1016/0006-2952(86)90414-4  0.372
1986 De Ceballos ML, Jenner P, Marsden CD. Acute and repeated administration of sulpiride alters Met-and Leu-enkephalin content of rat brain. Neuroscience Letters. 68: 322-6. PMID 3748458 DOI: 10.1016/0304-3940(86)90510-0  0.376
1986 Rupniak NM, Briggs RS, Petersen MM, Mann S, Reavill C, Jenner P, Marsden CD. Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine. Clinical Neuropharmacology. 9: 282-92. PMID 3719573 DOI: 10.1097/00002826-198606000-00006  0.42
1986 Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Clinical Neuropharmacology. 9: 165-81. PMID 3708602 DOI: 10.1097/00002826-198604000-00008  0.323
1986 Gibb WR, Lees AJ, Jenner P, Marsden CD. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. Neuroscience Letters. 65: 79-83. PMID 3486388 DOI: 10.1016/0304-3940(86)90123-0  0.403
1986 Bradbury AJ, Costall B, Domeney AM, Jenner P, Kelly ME, Marsden CD, Naylor RJ. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature. 319: 56-7. PMID 3484542 DOI: 10.1038/319056A0  0.402
1986 Garvey J, Petersen M, Waters CM, Rose SP, Hunt S, Briggs R, Jenner P, Marsden CD. Administration of MPTP to the common marmoset does not alter cortical cholinergic function. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 129-34. PMID 3143064 DOI: 10.1002/Mds.870010207  0.416
1986 Nomoto M, Jenner P, Marsden CD. Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. European Journal of Pharmacology. 121: 123-8. PMID 3082655 DOI: 10.1016/0014-2999(86)90401-2  0.401
1986 Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet (London, England). 2: 639-40. PMID 2875360 DOI: 10.1016/S0140-6736(86)92471-2  0.62
1986 Moser A, Reavill C, Jenner P, Marsden CD, Cramer H. Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat. Experimental Brain Research. 62: 567-71. PMID 2873048 DOI: 10.1007/Bf00236035  0.405
1986 Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 88: 403-19. PMID 2871578 DOI: 10.1007/Bf00178501  0.315
1986 Testa B, Naylor R, Costall B, Jenner P, Marsden CD. Does an endogenous methylpyridinium analogue cause Parkinson's disease? The Journal of Pharmacy and Pharmacology. 37: 679-80. PMID 2867199 DOI: 10.1111/J.2042-7158.1985.Tb05116.X  0.35
1986 Jenner P, Taquet H, Mauborgne A, Benoliel JT, Cesselin F, Rose S, Javoy-Agid F, Agid Y, Marsden CD. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. Journal of Neurochemistry. 47: 1548-51. PMID 2428937 DOI: 10.1111/J.1471-4159.1986.Tb00793.X  0.392
1986 Kilpatrick GJ, Jenner P, Marsden CD. [125I]Spiperone is not a useful ligand for studying the CHAPS solubilized dopamine D-2 receptor from rat striatum. Journal of Pharmacy and Pharmacology. 38: 406-408. PMID 2423678 DOI: 10.1111/J.2042-7158.1986.Tb04601.X  0.359
1986 Jenner P, David Marsden C. Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends in Neurosciences. 9: 259. DOI: 10.1016/0166-2236(86)90072-X  0.388
1985 Rupniak NM, Kilpatrick G, Hall MD, Jenner P, Marsden CD. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology. 84: 512-9. PMID 6441952 DOI: 10.1007/Bf00431458  0.432
1985 Rupniak NM, Mann S, Hall MD, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology. 84: 503-11. PMID 6441951 DOI: 10.1007/BF00431457  0.321
1985 Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochemical Pharmacology. 34: 2755-63. PMID 4040370 DOI: 10.1016/0006-2952(85)90577-5  0.424
1985 Pratt JA, Rothwell J, Jenner P, Marsden CD. Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function. Neuropharmacology. 24: 361-73. PMID 4022263 DOI: 10.1016/0028-3908(85)90020-6  0.343
1985 Kelly E, Jenner P, Marsden CD. Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones. Neuroscience Letters. 56: 57-62. PMID 4011049 DOI: 10.1016/0304-3940(85)90440-9  0.42
1985 Fine A, Reynolds GP, Nakajima N, Jenner P, David Marsden C. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset Neuroscience Letters. 58: 123-126. PMID 3931004 DOI: 10.1016/0304-3940(85)90340-4  0.385
1985 Kelly E, Jenner P, Marsden CD. The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices. Biochemical Pharmacology. 34: 2655-62. PMID 3925957 DOI: 10.1016/0006-2952(85)90563-5  0.358
1985 Kelly E, Jenner P, Marsden CD. Evidence that [3H]dopamine is taken up and released from nondopaminergic nerve terminals in the rat substantia nigra in vitro. Journal of Neurochemistry. 45: 137-44. PMID 3923157 DOI: 10.1111/J.1471-4159.1985.Tb05485.X  0.384
1985 Nomoto M, Jenner P, Marsden CD. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neuroscience Letters. 57: 37-41. PMID 3162113 DOI: 10.1016/0304-3940(85)90037-0  0.414
1985 Dewar D, Jenner P, Marsden CD. Behavioural effects in rats of unilateral and bilateral injections of opiate receptor agonists into the globus pallidus. Neuroscience. 15: 41-6. PMID 2989729 DOI: 10.1016/0306-4522(85)90121-6  0.323
1985 Boyce S, Kelly E, Davis A, Fleminger S, Jenner P, Marsden CD. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. Biochemical Pharmacology. 34: 1665-9. PMID 2988552 DOI: 10.1016/0006-2952(85)90632-X  0.43
1985 Rupniak NM, Hall MD, Kelly E, Fleminger S, Kilpatrick G, Jenner P, Marsden CD. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. Journal of Neural Transmission. 62: 249-66. PMID 2863324 DOI: 10.1007/Bf01252240  0.431
1985 Kilpatrick GJ, Jenner P, Marsden CD. Properties of rat striatal D-2 dopamine receptors solubilized with the zwitterionic detergent CHAPS. Journal of Pharmacy and Pharmacology. 37: 320-328. PMID 2862240 DOI: 10.1111/J.2042-7158.1985.Tb05074.X  0.337
1985 Rupniak NMJ, Jenner P, Marsden CD. Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats Psychopharmacology. 85: 71-79. PMID 2858901 DOI: 10.1007/Bf00427326  0.328
1984 Dewar D, Jenner P, Marsden CD. Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour. Experimental Brain Research. 52: 281-92. PMID 6641888 DOI: 10.1007/Bf00236638  0.345
1984 Kelly E, Jenner P, Marsden CD. Behavioural effects mediated by unilateral nigral dopamine receptor stimulation in the rat. Experimental Brain Research. 55: 243-52. PMID 6611272 DOI: 10.1007/Bf00237275  0.43
1984 Boyce S, Kelly E, Reavill C, Jenner P, Marsden CD. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochemical Pharmacology. 33: 1747-52. PMID 6610420 DOI: 10.1016/0006-2952(84)90344-7  0.439
1984 Rupniak NMJ, Jenner P, Marsden CD. Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatment Neuroscience Letters. 50: 63-65. PMID 6541767 DOI: 10.1016/0304-3940(84)90463-4  0.392
1984 Murugaiah K, Fleminger S, Hall MD, Theodorou A, Jenner P, Marsden CD. Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats Neuropharmacology. 23: 599-609. PMID 6540376 DOI: 10.1016/0028-3908(84)90139-4  0.395
1984 Hall MD, Cooper DR, Fleminger S, Rupniak NMJ, Jenner P, Marsden CD. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of l-DOPA to rats Neuropharmacology. 23: 545-553. PMID 6539859 DOI: 10.1016/0028-3908(84)90028-5  0.445
1984 Reavill C, Muscatt S, Leigh PN, Jenner P, Marsden CD. Enhanced GABA function in the angular complex (lateral periaqueductal grey matter and adjacent reticular formation) alters the postural component of striatal- or nigral-derived circling. Experimental Brain Research. 56: 1-11. PMID 6468558 DOI: 10.1007/Bf00237436  0.319
1984 Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neuroscience Letters. 50: 85-90. PMID 6436758 DOI: 10.1016/0304-3940(84)90467-1  0.446
1984 Leigh PN, Reavill C, Jenner P, Marsden CD. Basal ganglia outflow pathways and circling behaviour in the rat. Journal of Neural Transmission. 58: 1-41. PMID 6418859 DOI: 10.1007/Bf01249122  0.327
1984 Hall MD, Jenner P, Kelly E, Marsden CD. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat. British Journal of Pharmacology. 79: 599-610. PMID 6418246 DOI: 10.1111/J.1476-5381.1983.Tb11035.X  0.375
1984 Rupniak NM, Boyce S, Jenner P, Marsden CD. Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluorperazine for 15 months. Neuropharmacology. 23: 893-8. PMID 6148709 DOI: 10.1016/0028-3908(84)90002-9  0.34
1984 Chivers JK, Hall MD, Kelly E, Jenner P, Marsden CD. Dopamine receptor binding sites in the rat superior colliculus. The Journal of Pharmacy and Pharmacology. 36: 484-8. PMID 6146700 DOI: 10.1111/J.2042-7158.1984.Tb04434.X  0.352
1984 Kerwin R, Rupniak NMJ, Jenner P, Marsden CD. Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoperazine Neuroscience Letters. 45: 329-334. PMID 6145129 DOI: 10.1016/0304-3940(84)90247-7  0.348
1984 Kerwin RW, Rupniak NM, Jenner P, Marsden CD. A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [3H]glutamate and [3H]acetylcholine from rat striatal slices. Neuroscience. 11: 205-10. PMID 6143281 DOI: 10.1016/0306-4522(84)90224-0  0.336
1984 Kilpatrick GJ, Jenner P, Marsden CD. The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes European Journal of Pharmacology. 107: 71-78. PMID 6084599 DOI: 10.1016/0014-2999(84)90093-1  0.388
1984 Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden GD. DIFFERENTIAL EFFECTS OF ADMINISTRATION OF HALOPERIDOL, SULPIRIDE OR CLOZAPINE FOR 12 MONTHS ON RAT STRIATAL FUNCTION Clinical Neuropharmacology. 7: S298. DOI: 10.1097/00002826-198406001-00268  0.346
1983 Murugaiah K, Theodorou A, Jenner P, Marsden CD. Alterations in cerebral dopamine function caused by administration of cis- or trans-flupenthixol for up to 18 months Neuroscience. 10: 811-819. PMID 6685826 DOI: 10.1016/0306-4522(83)90218-X  0.373
1983 Murugaiah K, Fleminger S, Theodorou A, Jenner P, Marsden CD. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake Biochemical Pharmacology. 32: 2495-2499. PMID 6684429 DOI: 10.1016/0006-2952(83)90008-4  0.381
1983 Hall MD, Jenner P, Marsden CD. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. Biochemical Pharmacology. 32: 2973-7. PMID 6626267 DOI: 10.1016/0006-2952(83)90405-7  0.303
1983 Reavill C, Jenner P, Marsden CD. Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways. Biochemical Pharmacology. 32: 865-870. PMID 6301501 DOI: 10.1016/0006-2952(83)90589-0  0.413
1983 Luscombe G, Jenner P, Marsden CD. Alterations in brain 5HT and tryptamine content during indoleamine-induced myoclonus in guinea pigs Biochemical Pharmacology. 32: 1857-1864. PMID 6192824 DOI: 10.1016/0006-2952(83)90050-3  0.324
1983 Hall MD, Jenner P, Marsden CD. Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine. European Journal of Pharmacology. 87: 85-94. PMID 6188621 DOI: 10.1016/0014-2999(83)90053-5  0.4
1983 Rupniak N, Hong M, Mansfield S, Fleminger S, Dyer R, Jenner P, Marsden CD. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity. European Journal of Pharmacology. 93: 195-200. PMID 6139285 DOI: 10.1016/0014-2999(83)90137-1  0.433
1983 Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. Biochemical Pharmacology. 32: 2921-7. PMID 6138043 DOI: 10.1016/0006-2952(83)90397-0  0.395
1983 Rupniak NMJ, Jenner P, Marsden CD. Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats Psychopharmacology. 79: 226-230. PMID 6133305 DOI: 10.1007/Bf00427817  0.342
1983 Rupniak NMJ, Jenner P, Marsden CD. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sciences. 32: 2289-2311. PMID 6133203 DOI: 10.1016/0024-3205(83)90759-2  0.417
1983 Reynolds LM, Dyer RG, Jenner P, Marsden CD. Hypophysectomy does not prevent increased cerebral dopamine turnover following sulpiride administration. The Journal of Pharmacy and Pharmacology. 35: 170-4. PMID 6132975 DOI: 10.1111/J.2042-7158.1983.Tb04299.X  0.428
1983 Luscombe G, Jenner P, Marsden CD. Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems. Neuropharmacology. 21: 1257-65. PMID 6130489 DOI: 10.1016/0028-3908(82)90130-7  0.324
1983 Jenner P, Kerwin R, Rupniak NMJ, Murugaiah K, Hall MD, Fleminger S, Marsden CD. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. Journal of Neural Transmission-Supplement. 18: 205-212. DOI: 10.1007/978-3-7091-4408-4_19  0.418
1983 Anker L, Testa B, Van De Waterbeemd H, Bornand-Crausaz A, Theodorou A, Jenner P, Marsden CD. Basicity, Lipophilicity, and Lack of Receptor Interaction ofN-Aminoalkylbenzamides andN-Aminoalkyl-o-anisamides as Model Compounds of Dopamine Antagonists Helvetica Chimica Acta. 66: 542-556. DOI: 10.1002/Hlca.19830660215  0.315
1982 Taylor RJ, Reavill C, Jenner P, Marsden CD. Circling behavior following unilateral kainic acid injections into rat striatum. European Journal of Pharmacology. 76: 211-22. PMID 7333356 DOI: 10.1016/0014-2999(81)90503-3  0.347
1982 Jenner P, Hall MD, Murugaiah K, Rupniak N, Theodorou A, Marsden CD. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity Biochemical Pharmacology. 31: 325-328. PMID 7200363 DOI: 10.1016/0006-2952(82)90178-2  0.433
1982 Murugaiah K, Mann S, Theodorou AE, Jenner P, Marsden CD. Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors Life Sciences. 31: 181-188. PMID 6889662 DOI: 10.1016/0024-3205(82)90431-3  0.383
1982 Reavill C, Leigh PN, Jenner P, Marsden CD. Drug-induced circling after unilateral 6-hydroxydopamine lesions of the nigro-striatal pathway is mediated via the midbrain periaqueductal grey and adjacent reticular formation (angular complex). Life Sciences. 29: 2357-65. PMID 6798349 DOI: 10.1016/0024-3205(81)90471-9  0.323
1982 Fleminger S, Jenner P, Marsden CD. Are dopamine receptors present on human lymphocytes Journal of Pharmacy and Pharmacology. 34: 658-663. PMID 6128389 DOI: 10.1111/J.2042-7158.1982.Tb04696.X  0.345
1982 Murugaiah K, Theodorou A, Mann S, Clow A, Jenner P, Marsden CD. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum Nature. 296: 570-572. PMID 6122161 DOI: 10.1038/296570a0  0.308
1982 Jenner P, Rupniak NM, Hall MD, Dyer R, Leigh N, Marsden CD. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment. European Journal of Pharmacology. 76: 31-6. PMID 6119220 DOI: 10.1016/0014-2999(81)90006-6  0.42
1982 Rupniak NM, Jenner P, Marsden CD. The absence of sodium ions does not explain the failure of sulpiride to inhibit, in vitro, rat striatal dopamine-sensitive adenylate cyclase. The Journal of Pharmacy and Pharmacology. 33: 602-3. PMID 6117643 DOI: 10.1111/J.2042-7158.1981.Tb13877.X  0.36
1981 Luscombe G, Jenner P, Marsden CD. Pharmacological analysis of the myoclonus induced by 5-hydroxytryptophan in the guinea pig suggests the presence of multiple 5-hydroxytryptamine receptors in the brain. Neuropharmacology. 20: 819-31. PMID 7290355 DOI: 10.1016/0028-3908(81)90074-5  0.313
1981 Reavill C, Jenner P, Leigh N, Marsden CD. The role of nigral projections to the thalamus in drug-induced circling behaviour in the rat. Life Sciences. 28: 1457-66. PMID 7017327 DOI: 10.1016/0024-3205(81)90377-5  0.363
1981 Theodorou A, Reavill C, Jenner P, Marsden CD. Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D-2 receptors exist post-synaptically on corticostriate afferents and striatal neurons Journal of Pharmacy and Pharmacology. 33: 439-444. PMID 6115030 DOI: 10.1111/J.2042-7158.1981.Tb13829.X  0.332
1981 Kolbe H, Clow A, Jenner P, Marsden CD. Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors. Neurology. 31: 434-9. PMID 6111766 DOI: 10.1212/Wnl.31.4.434  0.416
1981 Marsden C, Jenner P. L-dopa's action in parkinson's disease Trends in Neurosciences. 4: 148-150. DOI: 10.1016/0166-2236(81)90049-7  0.363
1980 Schachter M, Bédard P, Debono AG, Jenner P, Marsden CD, Price P, Parkes JD, Keenan J, Smith B, Rosenthaler J, Horowski R, Dorow R. The role of D-1 and D-2 receptors. Nature. 286: 157-9. PMID 7402308 DOI: 10.1038/286157A0  0.338
1980 Clow A, Theodorou A, Jenner P, Marsden CD. A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration Psychopharmacology. 69: 227-233. PMID 6774362 DOI: 10.1007/Bf00433087  0.431
1980 Jenner P, Marsden CD, Thanki CM. Behavioural Changes Induced By N,N‐Dimethyltryptamine In Rodents British Journal of Pharmacology. 69: 69-80. PMID 6769527 DOI: 10.1111/J.1476-5381.1980.Tb10884.X  0.369
1980 Theodorou AE, Hall MD, Jenner P, Marsden CD. Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations Journal of Pharmacy and Pharmacology. 32: 441-444. PMID 6106685 DOI: 10.1111/J.2042-7158.1980.Tb12965.X  0.313
1980 Clow A, Theodorou A, Jenner P, David Marsden C. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration European Journal of Pharmacology. 63: 145-157. PMID 6103814 DOI: 10.1016/0014-2999(80)90438-0  0.413
1980 Clow A, Theodorou A, Jenner P, Marsden CD. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic European Journal of Pharmacology. 63: 135-144. PMID 6103813 DOI: 10.1016/0014-2999(80)90437-9  0.408
1980 Reavill C, Jenner P, Marsden CD. Metabolite involvement in bromocriptine-induced circling behaviour in rodents. The Journal of Pharmacy and Pharmacology. 32: 278-84. PMID 6103058 DOI: 10.1111/J.2042-7158.1980.Tb12912.X  0.331
1980 Jenner P, Clow A, Reavill C, Theodorou A, Marsden CD. Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms Journal of Pharmacy and Pharmacology. 32: 39-44. PMID 6102125 DOI: 10.1111/J.2042-7158.1980.Tb12842.X  0.435
1980 Reavill C, Leigh N, Jenner P, Marsden CD. Dopamine-mediated circling behaviour does not involve the nigro-tectal pathway. Experimental Brain Research. 37: 309-16. PMID 315328 DOI: 10.1007/Bf00237716  0.411
1980 Jenner P. The Neurobiology of Dopamine Journal of Neurology, Neurosurgery & Psychiatry. 43: 1150-1150. DOI: 10.1136/Jnnp.43.12.1150-B  0.377
1979 Clow A, Jenner P, Theodorou A, Marsden CD. Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months [15] Nature. 278: 59-61. PMID 570253 DOI: 10.1038/278059A0  0.413
1979 Reavill C, Jenner P, Leigh N, Marsden CD. Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components. Neuroscience Letters. 12: 323-8. PMID 460728 DOI: 10.1016/0304-3940(79)96083-X  0.328
1979 Clow A, Jenner P, Theodorou A, Marsde CD. NEUROLEPTIC DRUGS AND THE DOPAMINE HYPOTHESIS The Lancet. 313: 934. PMID 86713 DOI: 10.1016/S0140-6736(79)91424-7  0.36
1979 Jenner P, Marsden CD. The substituted benzamides--a novel class of dopamine antagonists. Life Sciences. 25: 479-485. PMID 40086 DOI: 10.1016/0024-3205(79)90559-9  0.371
1979 Clow A, Jenner P, Marsden CD. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. European Journal of Pharmacology. 57: 365-75. PMID 39769 DOI: 10.1016/0014-2999(79)90499-0  0.391
1979 Theodorou A, Crockett M, Jenner P, Marsden CD. Specific binding of [3H]sulpiride to rat striatal preparations Journal of Pharmacy and Pharmacology. 31: 424-426. PMID 39154 DOI: 10.1111/J.2042-7158.1979.Tb13545.X  0.304
1979 Luscombe G, Clow A, Jenner P, Marsden CD. Antagonism by propranolol of central dopamine receptor stimulation is not related to beta-adrenergic blockade. The Journal of Pharmacy and Pharmacology. 31: 355-6. PMID 37316 DOI: 10.1111/J.2042-7158.1979.Tb13522.X  0.326
1978 Jenner P, Clow A, Reavill C, Theodorou A, Marsden CD. A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs Life Sciences. 23: 545-549. PMID 692279 DOI: 10.1016/0024-3205(78)90032-2  0.416
1978 Chadwick D, Gorrod JW, Jenner P, Marsden CD, Reynolds EH. Functional changes in cerebral 5-hydroxytryptamine metabolism in the mouse induced by anticonvulsant drugs. British Journal of Pharmacology. 62: 115-24. PMID 620092 DOI: 10.1111/J.1476-5381.1978.Tb07013.X  0.303
1978 Clow A, Jenner P, Marsden CD. An experimental model of tardive dyskinesias. Life Sciences. 23: 421-3. PMID 567729 DOI: 10.1016/0024-3205(78)90146-7  0.396
1978 Jenner P, Pycock C, Marsden CD. The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity. Psychopharmacology. 58: 131-6. PMID 98779 DOI: 10.1007/Bf00426895  0.434
1978 Elliott PNC, Jenner P, Marsden CD. Atropine manipulation of elevated cerebral dopamine turnover caused by haloperidol or substituted benzamide drugs. Journal of Pharmacy and Pharmacology. 30: 788-791. PMID 32246 DOI: 10.1111/J.2042-7158.1978.Tb13394.X  0.378
1978 Jenner P, Elliott PN, Clow A, Reavill C, Marsden CD. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs. The Journal of Pharmacy and Pharmacology. 30: 46-8. PMID 22724 DOI: 10.1111/J.2042-7158.1978.Tb13151.X  0.371
1977 Sawaya MC, Dolphin A, Jenner P, Marsden CD, Meldrum BS. Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. Biochemical Pharmacology. 26: 1877-84. PMID 911341 DOI: 10.1016/0006-2952(77)90161-7  0.338
1977 Dolphin A, Christina M, Sawaya MC, Jenner P, Marsden CD. Behavioural and biochemical effects of chronic reduction of cerebral noradrenaline receptor stimulation. Naunyn-Schmiedeberg's Archives of Pharmacology. 299: 167-73. PMID 909612 DOI: 10.1007/Bf00498559  0.365
1977 Donaldson IM, Dolphin AC, Jenner P, Pycock C, Marsden CD. Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles. Brain Research. 138: 487-509. PMID 597720 DOI: 10.1016/0006-8993(77)90685-0  0.387
1977 Elliott PN, Jenner P, Huizing G, Marsden CD, Miller R. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 16: 333-42. PMID 559256 DOI: 10.1016/0028-3908(77)90070-3  0.436
1977 Pycock CJ, Jenner PG, Marsden CD. The interaction of clonidine with dopamine-dependent behaviour in rodents. Naunyn-Schmiedeberg's Archives of Pharmacology. 297: 133-41. PMID 558529 DOI: 10.1007/BF00499922  0.326
1977 Dolphin AC, Jenner P, Sawaya MC, Marsden CD, Testa B. The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents. The Journal of Pharmacy and Pharmacology. 29: 727-34. PMID 22618 DOI: 10.1111/J.2042-7158.1977.Tb11450.X  0.429
1976 Dolphin A, Jenner P, Marsden CD. Modification of the L-DOPA reversal of reserpine akinesia by inhibitors of dopamine-beta-hydroxylase. European Journal of Pharmacology. 35: 135-44. PMID 1253815 DOI: 10.1016/0014-2999(76)90308-3  0.453
1976 Dolphin A, Jenner P, Marsden CD. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacology, Biochemistry, and Behavior. 5: 431-9. PMID 1005491 DOI: 10.1016/0091-3057(76)90107-6  0.411
1976 Donaldson IM, Dolphin A, Jenner P, Marsden CD, Pycock C. The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. Brain : a Journal of Neurology. 99: 427-46. PMID 1000281 DOI: 10.1093/Brain/99.3.427  0.39
1976 Dolphin AC, Jenner P, Marsden CD. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacology, Biochemistry, and Behavior. 4: 661-70. PMID 981283 DOI: 10.1016/0091-3057(76)90217-3  0.416
1976 Donaldson I, Dolphin A, Jenner P, Marsden CD, Pycock C. The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus. European Journal of Pharmacology. 39: 179-91. PMID 976315 DOI: 10.1016/0014-2999(76)90126-6  0.392
Show low-probability matches.